Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Vertex Pharmaceuticals Inc., solvency ratios (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Debt Ratios
Debt to equity
Debt to equity (including operating lease liability)
Debt to capital
Debt to capital (including operating lease liability)
Debt to assets
Debt to assets (including operating lease liability)
Financial leverage
Coverage Ratios
Interest coverage

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Debt Ratios
The debt to equity ratio, when including operating lease liabilities, remained relatively stable and low between March 2021 and June 2024, fluctuating mainly between 0.02 and 0.04. From June 2024 onward, there is a noticeable increase to around 0.09-0.10, indicating a higher proportion of debt relative to equity in this later period.
Similarly, the debt to capital ratio including operating lease liabilities mirrors this trend with consistent low values around 0.02 to 0.04 through early 2024, then rising to approximately 0.08 to 0.09 after June 2024. This suggests a greater reliance on debt financing relative to total capital in the recent periods.
The debt to assets ratio including operating lease liabilities remained stable and low, typically between 0.02 and 0.03 until mid-2024. It then experienced an increase to about 0.06–0.07 towards mid-2025, signifying a higher debt level relative to total assets.
Financial Leverage
Financial leverage ratios were fairly steady from March 2021 through early 2024, generally varying between 1.28 and 1.36. However, starting from mid-2024, the leverage increased progressively, reaching approximately 1.40 by mid-2025. This upward trend indicates expanding use of debt relative to equity to fund the company's assets.
Interest Coverage
Interest coverage ratios exhibited strong levels from March 2021 to early 2024, with values ranging from around 40 to over 110, reflecting a healthy ability to cover interest expenses from earnings. Nevertheless, a significant dip is evident at the end of 2024 and beginning of 2025, with the ratio dropping sharply to negative values before rebounding dramatically to over 250 by mid-2025. This volatility could be indicative of fluctuations in earnings or interest expense during these quarters.
Overall Insights
Across the observed periods, the company maintained low leverage and debt levels relative to equity, capital, and assets for the majority of the four-year timeframe. A marked shift occurred starting mid-2024, with increasing leverage and debt ratios suggesting a strategic change to incorporate more debt financing. Despite this, the company generally sustained strong interest coverage, indicating robust earnings relative to debt servicing costs, except for a brief period of significant volatility in late 2024 and early 2025.

Debt Ratios


Coverage Ratios


Debt to Equity

Vertex Pharmaceuticals Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial data over the periods available reveal consistent developments in shareholders' equity without recorded data for total debt and debt-to-equity ratios. The patterns observed focus solely on equity changes.

Shareholders' Equity Trends
The shareholders' equity has shown a steady upward trajectory from March 31, 2021, through June 30, 2025, with values increasing almost every quarter. Starting at approximately $8.98 billion at the beginning of 2021, the equity rose progressively to reach about $17.18 billion by mid-2025. This reflects an overall growth in the company's net asset base over the period.
Quarterly Growth Patterns
The increases in shareholders' equity seem to be relatively stable and continuous, with no significant declines or volatile fluctuations. Noteworthy is the quarterly rise from early 2021 through the end of 2023, where equity grew from roughly $9 billion to about $17.58 billion, nearly doubling in this span. There was a slight dip observed in June 2024 where equity decreased from around $18.55 billion in March 2024 to approximately $14.77 billion, indicating a possible revaluation, adjustment, or a one-off event reducing equity. Following this, equity resumed its growth trajectory.
Data Gaps and Implications
The absence of recorded values for total debt and debt-to-equity ratios limits the comprehensive analysis of the company's capital structure and leverage. Without these data points, evaluating risk levels or financial strategy in terms of debt usage and equity financing is not possible. The continuous increase in shareholders' equity alone suggests a strengthening equity base, although the lack of debt information means the overall balance sheet strength cannot be fully assessed.
Summary
In summary, the company displays consistent growth in shareholders' equity over the reviewed time frame. The equity base nearly doubled over four and a half years, with only a minor and temporary decline. This likely indicates good profitability, retained earnings accumulation, or successful equity issuance, contingent on company actions not detailed here. Monitoring of debt data would be necessary to form a complete assessment of financial health and capital management.

Debt to Equity (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Shareholders’ equity
Solvency Ratio
Debt to equity (including operating lease liability)1

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =


The financial data indicates several notable trends over the observed periods. Total debt, including operating lease liabilities, remained relatively stable from March 2021 through December 2023, fluctuating modestly around the mid-300,000 US$ thousands mark. However, from March 2024 onwards, there was a significant increase in total debt, reaching peaks above 1,500,000 US$ thousands by mid-2025.

Shareholders’ equity demonstrated a consistent upward trajectory throughout most of the periods, starting from approximately 8,980,000 US$ thousands in March 2021 and growing steadily to roughly 17,580,000 US$ thousands by December 2023. After that, there was a dip in equity value in the early periods of 2024 but it recovered and continued to increase through mid-2025, reaching above 17,100,000 US$ thousands.

The debt to equity ratio remained low and stable during the majority of the timeline, fluctuating between 0.02 to 0.04, indicating a conservative leverage position through December 2023. From March 2024, this ratio increased noticeably, peaking around 0.10 by mid-2025, reflecting the substantial rise in total debt compared to equity.

Total Debt Trend
Stable at moderate levels until end of 2023, followed by sharp increase in 2024 and 2025.
Shareholders’ Equity Trend
Consistent growth through 2023 with a temporary dip in early 2024, then resumption of growth through 2025.
Debt to Equity Ratio
Low and stable until late 2023, then rising significantly in 2024 and 2025 due to increased debt.

Overall, the company maintained a strong equity base with conservative leverage for most of the period reviewed. The notable increase in debt starting in early 2024 suggests a strategic shift towards higher leverage, which could imply greater financing activities or investments that may warrant further examination in subsequent reports.


Debt to Capital

Vertex Pharmaceuticals Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The quarterly financial data reveals key aspects of the capital structure and related metrics over the reported periods. Although data for total debt and debt to capital ratio are not provided, the total capital figures exhibit a distinct trend worthy of analysis.

Total Capital
The total capital, reported in thousands of US dollars, demonstrates consistent growth from the earliest available data point of 8,980,254 in March 2021 through to a peak of approximately 18,546,600 in March 2024. This escalation indicates significant capital expansion over three years, reflecting possible funding inflows or asset base increases.
After reaching the peak in early 2024, total capital shows a marked decline to 14,774,700 by June 2024. Following this drop, a recovery trend occurs, with total capital increasing steadily once more, reaching about 17,175,400 by June 2025. This pattern suggests a period of capital reduction, possibly due to strategic divestitures, repayments, or revaluation before resuming growth.

Although the absence of total debt data precludes direct analysis of leverage trends or the calculation of debt to capital ratio, the growth and fluctuations in total capital alone suggest active management of the company’s financing structure during the timeframe. The sharp decline in mid-2024 warrants particular attention as it deviates from the otherwise consistent upward trend, implying potential operational or strategic shifts.


Debt to Capital (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
Shareholders’ equity
Total capital (including operating lease liability)
Solvency Ratio
Debt to capital (including operating lease liability)1

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =


The analysis of the financial data reveals several notable trends in the company's capital structure and debt levels over the periods presented.

Total Debt (Including Operating Lease Liability)
The total debt remained relatively stable from March 2021 through December 2023, fluctuating modestly between approximately $348 million and $379 million. Starting from March 2024, there is a marked increase in total debt, rising sharply from approximately $360 million to nearly $1.59 billion by September 2024. Subsequently, the debt level slightly decreases but remains elevated above $1.5 billion through June 2025. This significant rise suggests a substantial increase in the company's leverage or financing activities during this later period.
Total Capital (Including Operating Lease Liability)
The total capital exhibits a consistent upward trajectory from March 2021, starting at about $9.35 billion, and reaching $17.9 billion by December 2023. However, in the first half of 2024, total capital decreases notably to approximately $15.36 billion before recovering and continuing upward to $18.7 billion by June 2025. Despite some volatility, the overall capital base grows substantially over the analyzed period, reflecting either retained earnings, new equity issuance, or other capital inflows.
Debt to Capital Ratio (Including Operating Lease Liability)
This ratio indicates the proportion of debt relative to total capital. From March 2021 to December 2023, the ratio remains low and stable, fluctuating between 0.02 and 0.04, indicating a conservative leverage position. Starting in March 2024, the ratio increases sharply to approximately 0.09, parallel with the spike in total debt. This elevated debt-to-capital ratio sustains through June 2025, remaining near 0.08–0.09, which reflects a higher leverage level compared to previous periods.

In summary, the company maintained low leverage with stable total debt and steadily increasing capital through 2023. A significant increase in debt and relative leverage occurred beginning in early 2024, accompanied by a temporary dip in total capital. This shift suggests a strategic change in funding or financing structure, potentially aimed at supporting new initiatives or managing cash flow. Monitoring future quarters will be important to assess whether this higher leverage level is temporary or part of a longer-term capital strategy.


Debt to Assets

Vertex Pharmaceuticals Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals several important trends regarding the company's total assets over recent quarters. While information on total debt and the debt to assets ratio is not available for analysis, the total assets figures provide insight into the overall asset growth trajectory.

Total Assets
The total assets increased consistently from March 31, 2021, through March 31, 2025, with occasional fluctuations in the later quarters. Starting at approximately 12.1 billion USD in the first quarter of 2021, the assets grew steadily each quarter to reach around 24 billion USD by mid-2025.
This growth depicts a more than doubling of total assets over this 4-year period, indicating substantial expansion in the company's asset base.
Between March 31, 2024, and June 30, 2024, there is a notable decline, with assets dropping from approximately 23.9 billion USD to 20.1 billion USD. However, from that point forward, total assets recovered and resumed an upward course, reaching 24 billion USD by June 30, 2025.
This short-term decrease could suggest asset sales, write-downs, or other reclassification events during that period, followed by a recovery phase in subsequent quarters.

Because total debt and the debt to asset ratio data are missing, it is not possible to assess leverage or the company's indebtedness trends relative to its asset base. The absence limits insights into the financial risk profile and capital structure changes over time.

Overall, the asset trend reflects consistent growth with a temporary contraction, indicating active asset management and growth efforts by the company over the reviewed period.


Debt to Assets (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Total assets
Solvency Ratio
Debt to assets (including operating lease liability)1

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =


The analysis of the financial data reveals several notable trends regarding the company’s leverage and asset base over the observed quarters.

Total Debt (including operating lease liability)
The total debt level remained relatively stable from March 2021 through December 2023, fluctuating modestly around the 350,000 to 380,000 thousand US dollar range. Starting from March 2024, there is a marked increase in total debt, with a sharp rise peaking significantly above 1,500,000 thousand US dollars by June 2025. This indicates a substantial uptick in leverage or borrowings during the most recent quarters compared to prior periods.
Total Assets
Total assets demonstrated a consistent growth trajectory throughout most of the observed period. From March 2021 to December 2023, assets increased steadily from approximately 12,115,000 thousand US dollars to over 22,730,200 thousand US dollars. However, starting in March 2024, assets displayed some volatility, with a notable dip in mid-2024, followed by subsequent recovery by mid-2025, ultimately reaching around 24,036,700 thousand US dollars. This pattern suggests active asset management with periods of divestiture or revaluation, followed by expansion or acquisition.
Debt to Assets Ratio
This ratio was maintained at a low level, around 0.02 to 0.03, during the majority of the timeline from 2021 through early 2024, reflecting conservative leverage relative to asset size. Beginning in March 2024, the ratio increased significantly to approximately 0.07 through mid-2025, paralleling the sharp increase in total debt. Despite this rise, the ratio remains below 0.1, indicating that overall debt levels are still moderate relative to total assets, but the trend points to a strategic shift toward higher leverage.

In summary, the company sustained steady asset growth and low debt levels for several years before a pronounced increase in debt commencing in early 2024. This rise in indebtedness, coupled with a stable yet slightly fluctuating asset base, led to an increase in the debt-to-assets ratio. The trends imply a deliberate change in financial policy, possibly aimed at funding expansion or other strategic initiatives requiring greater external financing. Close monitoring of leverage and asset quality will be critical moving forward to assess financial risk and operational efficiency.


Financial Leverage

Vertex Pharmaceuticals Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total assets
Shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Total Assets
The total assets show a generally increasing trend over the periods analyzed, rising from approximately $12.1 billion to around $24.0 billion. There is consistent growth quarter over quarter until the first quarter of 2024, where a notable dip occurs, with total assets decreasing from about $23.9 billion to $20.1 billion. Following this decline, the assets again resume growth, recovering to near $22.4 billion by the third quarter of 2024 and maintaining a steady increase up to approximately $24.0 billion by mid-2025. Overall, the long-term trend reflects expansion in asset base despite short-term fluctuations.
Shareholders’ Equity
Shareholders’ equity demonstrated a steady rise from about $9.0 billion to $18.5 billion by the first quarter of 2024, mirroring the asset growth. However, a significant contraction occurs coinciding with the decrease in total assets during the same period, dropping to roughly $14.8 billion in the second quarter of 2024. After this decline, equity follows a recovery path, increasing to approximately $16.6 billion by the end of 2024 and further to $17.2 billion by mid-2025. This pattern indicates that the fluctuations in shareholders’ equity closely align with movements in total assets, suggesting changes in retained earnings or other equity components during these periods.
Financial Leverage
The financial leverage ratio remained relatively stable and low, fluctuating narrowly between 1.28 and 1.4 across the full timeline. Initially, leverage decreased gradually from 1.35 to around 1.28, indicating a slight reduction in reliance on debt relative to equity. However, starting from early 2024, leverage increased moderately, peaking at 1.42 in the second quarter of 2024, coinciding with the declines in assets and equity noted previously. Subsequently, the ratio moderated somewhat but stayed elevated relative to early years, averaging around 1.39 by mid-2025. This suggests a modest increase in financial risk or a shift in capital structure towards greater use of liabilities during the latter periods analyzed.
Summary Insights
The data reveal robust asset and equity growth across most periods, indicative of expansion and strengthening capital base. Nonetheless, the significant asset and equity decline in early 2024, coupled with a rise in financial leverage, points to an event or condition impacting financial structure adversely during that time. Recovery afterward signals management’s efforts to restore financial health. The consistently low but slightly rising leverage ratio suggests the company maintains a conservative debt profile overall, while adapting its capital structure as needed in response to external or internal pressures. Close monitoring of leverage dynamics will be important moving forward to ensure sustainable financial stability.

Interest Coverage

Vertex Pharmaceuticals Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Net income (loss)
Add: Income tax expense
Add: Interest expense
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
Amgen Inc.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q2 2025 Calculation
Interest coverage = (EBITQ2 2025 + EBITQ1 2025 + EBITQ4 2024 + EBITQ3 2024) ÷ (Interest expenseQ2 2025 + Interest expenseQ1 2025 + Interest expenseQ4 2024 + Interest expenseQ3 2024)
= ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Earnings Before Interest and Tax (EBIT)
The EBIT figures demonstrate significant volatility across the periods. Starting with a positive value of approximately $837 million in the first quarter of 2021, EBIT experienced a sharp decline into negative territory in the subsequent quarter. However, it quickly rebounded to over $1 billion by the third quarter of 2021. Throughout 2022 and early 2023, EBIT generally remained strong, fluctuating between roughly $900 million and $1.2 billion. Notably, a major decline occurred in the second quarter of 2024, where EBIT dropped to a negative $3.38 billion, an outlier in the trend. Subsequently, EBIT returned to positive territory and stabilized around $700 million to $1.3 billion through mid-2025.
Interest Expense
Interest expenses show a steady declining trend over the entire period. Beginning at $15.7 million in the first quarter of 2021, the expense gradually decreased each quarter, reaching a low of $2.8 million in the second quarter of 2025. This indicates an effective reduction in the company’s debt servicing costs or improved financing conditions.
Interest Coverage Ratio
The interest coverage ratio remained robust throughout most periods, reflecting strong operational earnings relative to interest expenses. Initial values were very high, starting near 56 and progressively increasing to above 100 by early 2024, signifying ample earnings to cover interest obligations. However, the ratio dramatically plunged to 6.14 in the second quarter of 2024, coinciding with the EBIT loss reported in the same quarter. This decline suggests a temporary weakening of earnings relative to interest payments. The ratio then began to recover steadily, ending with a notably high value of 258.29 by the second quarter of 2025, indicating an exceptionally strong capacity to meet interest obligations at that time.
Overall Observations
The data highlights a generally robust financial performance with strong EBIT and declining interest expenses contributing to improved interest coverage over most of the analyzed periods. The anomalous negative EBIT and suppressed interest coverage ratio in the second quarter of 2024 suggest a significant, albeit temporary, operational challenge. Post this event, the firm demonstrated recovery and resilience, with operational earnings and interest coverage ratios returning to historically strong levels. The consistent reduction in interest expense over time supports enhanced financial flexibility and creditworthiness.